4//SEC Filing
ENRIGHT PATRICK G 4
Accession 0000950170-25-090110
CIK 0001831828other
Filed
Jun 24, 8:00 PM ET
Accepted
Jun 25, 8:07 PM ET
Size
11.9 KB
Accession
0000950170-25-090110
Insider Transaction Report
Form 4
ENRIGHT PATRICK G
Director
Transactions
- Purchase
Class A Common Stock
2025-06-23$20.87/sh+69,798$1,456,566→ 1,784,083 total(indirect: See footnote) - Purchase
Class A Common Stock
2025-06-23$20.87/sh+139,595$2,913,110→ 3,569,522 total(indirect: See footnote) - Purchase
Class A Common Stock
2025-06-24$22.35/sh+13,536$302,553→ 1,797,619 total(indirect: See footnote) - Purchase
Class A Common Stock
2025-06-24$22.35/sh+27,071$605,083→ 3,596,593 total(indirect: See footnote)
Footnotes (4)
- [F1]The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $20.43 to $21.05, inclusive. The Reporting Person undertakes to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4.
- [F2]These shares are held by Longitude Prime Fund, L.P. ("LPF"). Longitude Prime Partners, LLC ("LPP") is the general partner of LPF and may be deemed to have voting and investment power over the securities held by LPF. The Reporting Person and Juliet Tammenoms Bakker are the managing members of LPP and may be deemed to share voting and dispositive power over the shares held by LPF. Each of LPP, the Reporting Person and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
- [F3]These shares are held by Longitude Venture Partners IV, L.P ("LVPIV"). Longitude Capital Partners IV, LLC ("LCPIV") is the general partner of LVPIV and may be deemed to have voting and dispositive power over the shares held by LVPIV. The Reporting Person and Ms. Tammenoms Bakker are managing members of LCPIV and may be deemed to share voting and dispositive power with respect to the shares held by LVPIV. Each of LCPIV, the Reporting Person and Ms. Tammenoms Bakker disclaims beneficial ownership of such shares and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
- [F4]The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $21.67 to $22.50, inclusive. The Reporting Person undertakes to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 4 to this Form 4.
Documents
Issuer
Vera Therapeutics, Inc.
CIK 0001831828
Entity typeother
Related Parties
1- filerCIK 0001253886
Filing Metadata
- Form type
- 4
- Filed
- Jun 24, 8:00 PM ET
- Accepted
- Jun 25, 8:07 PM ET
- Size
- 11.9 KB